Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Forward Pharma A/S is a Danish biopharmaceutical company that commenced developmen...
Forward Pharma A/S is a Danish biopharmaceutica...
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
Cary is a vertically integrated and full service pharmacy that delivers prescripti...
Cary is a vertically integrated and full servic...
Siemens Healthineers AG is the holding company of the Siemens Healthineers group. ...
Siemens Healthineers AG is the holding company ...
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...
Astellas Pharma Inc. is a pharmaceutical compan...
Aileron Therapeutics is a clinical stage company discovering and developing novel ...
Aileron Therapeutics is a clinical stage compan...
Join the National Investor Network and get the latest information with your interests in mind.